1291 results about "Therapy medication" patented technology

The invention discloses a medical developing marker and a manufacturing method thereof, and relates to the field of medical instruments, the medical developing marker comprises a closed tube, the outer wall of the closed tube is provided with a bionic barb structure, the bionic barb structure is distributed in a flexible zigzag convex manner, and the bionic barb structure and the closed tube are integrally formed through an injection molding process; a closed cavity is arranged in the closed tube, four developing strips are symmetrically arranged in the tube wall of the closed cavity, the tube wall of the region where the developing strips are located is etched to form a weak band, and a developing material layer and a sustained-release medicine layer are sequentially deposited at the weak band. The developing material layer and the sustained-release drug and / or marked nano-particle layer are alternately deposited to form a functional composite layer, and the functional composite layer can directionally rupture to release the therapeutic drug under the action of implantation pressure. The marker integrates the functions of precise development, tissue anchoring and drug sustained release, is adaptive to multi-mode imaging such as ultrasonic imaging, X-ray imaging, CT imaging, MRI imaging and PET-CT imaging, and has remarkable clinical value in precise positioning treatment of solid tumors such as breast cancer and liver cancer.

The invention provides a construction method of a predictive cell senescence model, a method for predicting the senescence state of a tissue sample based on the senescence model, a method for screening potential therapeutic drugs, equipment, a medium and a program product, and relates to the field of intelligent medical treatment. The model construction method comprises the following steps: acquiring a training set sample expression profile data set; identifying a key senescence gene set from the data set by using a feature selection algorithm; inputting the key senescence gene set into a machine learning model to fit a prediction model, and determining an optimal hyper-parameter to obtain a cell senescence model containing the weight of a single gene in the key senescence gene set; the cell senescence model is a senescence score obtained by calculating the sum of the product of the expression quantity of a single gene and the regression coefficient thereof. The cell senescence model, namely PreCSenM, is constructed by integrating a plurality of senescence characteristic gene sets and a gene scoring algorithm, the accuracy in CS evaluation is superior to that of 10 existing methods, and the application of CS from biological research to clinical scenes is also realized.

The invention discloses an engineered bionic nucleic acid nano-vesicle as well as a preparation method and application thereof, relates to the technical field of nano biomedicine, and aims at solving the problems that in-vivo targeting efficiency and immunogenicity of a traditional cationic lipid nano-carrier are limited due to deletion and cleavage obstacles of GSDMD expression in tumor cells. The technical key point of the invention is as follows: the engineered bionic nucleic acid nano-vesicle is provided and is prepared by wrapping a cationic lipid nucleic acid drug with an exosome derived from engineered macrophages; wherein the exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1, which is as shown in SEQ. ID. NO.1. The exosome from the engineered macrophage is the exosome from the macrophage with high expression of PD1; the lipid nucleic acid medicine is prepared by loading GSDMD-N mRNA (messenger Ribonucleic Acid) shown on the basis of SEQ.ID.NO.2 on a cationic liposome. The engineered bionic nucleic acid nano-vesicle is used for preparing an oral squamous cell carcinoma diagnostic kit and a therapeutic drug.

The invention belongs to the technical field of biotechnology and animal models, and discloses a double-person-derived mouse model for simulating a tumor immune microenvironment and a construction method and application thereof. The method comprises the following steps: firstly, pretreating NSG immunodeficient mice by adopting low-dose whole-body irradiation in combination with double-antibody targeted bone marrow depletion, and transplanting CD34 + hematopoietic stem cells from the same human donor to complete human immune system reconstruction; separating tumor primary cells, tumor-related fibroblasts and tumor vascular endothelial cells of the same donor, performing three-dimensional co-culture to obtain homologous human tumor organs, and performing in-situ inoculation to immune reconstruction mice to obtain a target model. The core defects of MHC mismatching, low immune reconstruction efficiency, poor tumor immune microenvironment simulation degree, low clinical consistency and the like of an existing model are overcome, and the method can be used for tumor immune treatment drug screening, microenvironment mechanism research and personalized tumor treatment scheme verification.

Disclosed herein are heterocyclic compounds that activate GLP-1R pathways. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the GLP-1R agonists are disclosed, alone or in combination with other therapeutic agents, for the treatment of diabetes, obesity, and other diseases or conditions dependent on GLP-1R pathways.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

The invention discloses an anti-tumor medicine composition combined with a PARG inhibitor and application. Through natural product library screening and CCK-8 experiments, it is found that PARG knockout gastric cancer cells show significantly enhanced sensitivity to ginsenoside CK. Further clone formation experimental analysis shows that PARG knockout significantly enhances the inhibitory effect of ginsenoside CK on gastric cancer cell proliferation. In in-vivo experiments, a CDX model is utilized to verify that PARG knockout can significantly enhance the anti-tumor activity of ginsenoside CK on gastric cancer. The discovery provides an important experimental basis for clinical application of PARG as a gastric cancer treatment target and ginsenoside CK as a potential treatment drug. The research finds that the PARG inhibitor and ginsenoside CK are combined to achieve a better killing effect on other various cancer cells, and it is indicated that improvement of the effect is broad-spectrum.

The invention discloses a construction method and application of a mouse model for specifically tracing heart valve cells, and belongs to the technical field of animal model construction. The model construction method comprises the following steps: (1) constructing a Wid1-Cre hybrid mouse before inserting a Cre recombinase coding gene into a termination codon of a mouse Wid1 gene; and (2) hybridizing the Wid1-Cre hybrid mouse with the Rosa26-tdTomato homozygous report mouse, so as to obtain the double transgenic mouse which simultaneously carries the Wid1-Cre gene and the Rosa26-tdTomato gene. According to the invention, on the basis of the expression characteristic that Wif1 is only limited to a valve area in the heart, Wif1-Cre is constructed; according to the Rosa26-tdTomato mouse model, specific tracing of heart valve cells is achieved, and an important experimental tool is provided for mechanism research of heart valve diseases and development of therapeutic drugs.

The invention discloses design and synthesis of a series of brain-targeted ginsenoside Rg1 derivatives and application of the brain-targeted ginsenoside Rg1 derivatives in treatment of Alzheimer's disease. According to the invention, ginsenoside Rg1 and polyethylene glycol with a specific chain length are covalently linked to successfully construct the derivative capable of enhancing the penetrating power of the blood-brain barrier. The series of derivatives provided by the invention not only solve the problems of poor brain targeting and insufficient stability of natural Rg1, but also can inhibit neuroinflammation by regulating and controlling an NLRP3 / caspase-1 signal channel in an LPS-induced neuroinflammation model, and finally, the learning and memory ability is remarkably improved. The product is simple and convenient in preparation process and good in biological safety, and a new candidate compound is provided for developing a new generation of Alzheimer disease treatment medicines.

The invention belongs to the technical field of biological medicines, and discloses application of beta-elemonic acid or derivatives thereof or pharmaceutically acceptable salts thereof in preparation of medicines for preventing and / or treating polycystic ovarian syndrome (PCOS). The beta-elemonic acid is screened from a medicinal and edible library, and experiments prove that the beta-elemonic acid can remarkably improve the PCOS ovarian form and the number of mature follicles, normalize the disordered estrus cycle, remarkably improve the serum hormone level and further remarkably improve the sugar tolerance, insulin tolerance and weight of PCOS. The beta-elemonic acid disclosed by the invention is a compound based on homology of medicine and food, can be used as a medicine as well as a natural ingredient of food, is relatively low in toxicity, ensures the safety after long-term use, is relatively low in safety evaluation cost of a relatively brand-new synthetic compound, and can be applied to development and preparation of a medicine or a lead compound thereof for preventing and / or treating PCOS, or a health care product.

The invention discloses an application of imatinib mesylate in preparation of a targeted therapeutic drug for gastric signet ring cell carcinoma. The imatinib mesylate has an obvious inhibition effect on the growth of six patients with the pathological type of gastric signet-ring cell carcinoma, the inhibition effect is more obvious along with the increase of the concentration, the concentration and dosage dependency relationship is shown, and the half inhibitory concentration (IC50) is obviously smaller than that of a positive control drug apatinib. The medicine can play a targeted therapeutic role on the gastric signet ring cell carcinoma, and is small in toxic and side effects, economical, practical and low in cost.

The invention relates to the technical field of medicines, in particular to application of lasiokaurin and cis-platinum combined medicine in preparation of a medicine for treating liver cancer. As a diterpenoid compound, lasiokaurin shows significant potential in the anti-cancer field. However, in medical research and clinical application at present, related reports about combined use of lasiokaurin and a classical anti-cancer drug cis-platinum for treating liver cancer do not exist. Based on the current research situation, the invention creatively provides the application of the lasiokaurin and cis-platinum combined medicine in the aspect of preparing the liver cancer treatment medicine. In-depth study finds that lasiokaurin and cis-platinum can generate a synergistic effect and jointly play a strong anti-tumor role, and a brand new way is opened up for treatment of liver cancer.

The invention relates to the technical field of biological medicines and vaccines, in particular to a nano-selenium modified liposome as well as a preparation method and application thereof. The nano-selenium modified lipidosome disclosed by the invention comprises a lipidosome and nano-selenium. Wherein the nano-selenium is modified on the surface of the liposome; the liposome is composed of cholesterol, phospholipid, and distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000. The nano-selenium modified liposome can be suitable for different treatment scenes, becomes a multifunctional drug delivery platform, has the characteristics of long circulation, good biocompatibility, high drug loading rate, good stability, increase of retention time of a treatment drug in a body and the like, can be directly entrapped with an antigen, can also be cooperatively combined with a drug and a vaccine, and has a wide application prospect. The defects of low bioavailability, poor stability, toxic and side effects and the like of the existing medicinal preparation are overcome, and the immunotherapy effect is remarkably enhanced while the treatment medicine in the liposome is promoted to achieve a remarkable slow release effect.

The invention provides application of AQP1 protein as a target spot in preparation of a diagnostic reagent and a therapeutic drug for hypoglycaemia nephropathy, and belongs to the technical field of biological medicines.The AQP1 protein is used as the target spot, AQP1 protein expression is reduced by adopting an inhibitor, and the hypoglycaemia nephropathy is obtained. According to the present invention, with the application of the kit, the effects of reducing the renal tubule injury markers in the urine, reducing the glomerular filtration rate or relieving the kidney tissue hypoxia can be achieved, the new idea is provided for the early prevention and treatment of the diabetic nephropathy (DKD), and the early recognition and the effective treatment of the kidney injury of the diabetic patient can be well achieved.

The invention provides a multi-target degradation agent and application thereof, relates to the field of medicinal chemistry, and particularly provides a stereoisomer, N-oxide, deuterated derivative and pharmaceutically acceptable salt of the multi-target degradation agent shown in the formula (IA), all substituent groups in the formula are defined in the specification, and the compound can degrade BTK protein and / or IRAK4 protein. According to the present invention, the BTK and IRAK4 protein can be simultaneously degraded in a variety of tumor cells, the proliferation of the tumor cells can be efficiently inhibited, the apoptosis of the tumor cells can be induced, and the new treatment drug can be provided for cancers and other self-immune diseases.

The invention belongs to the technical field of biological medicines, and particularly relates to application of beta-hydroxybutyrate in preparation of a medicine for preventing or treating hepatocellular carcinoma. The invention provides an application of beta-hydroxybutyrate in preparation of a medicine for preventing and / or treating hepatocellular carcinoma. The beta-hydroxybutyrate comprises a beta-hydroxybutyrate or a combination of a plurality of beta-hydroxybutyrates. A series of experimental data show that beta-hydroxybutyrate not only can effectively improve fatty degeneration and inflammatory response of hepatocytes, but also can remarkably reduce the risk of occurrence of metabolic dysfunction related hepatocellular carcinoma (HCC), and can inhibit malignant biological characteristics of HCC. The invention provides a powerful scientific basis for the development of novel HCC prevention and treatment medicines, and has a wide clinical application prospect.

The invention relates to an application of a small molecule medicine STK000311 in a medicine for treating a cGAS-STING pathway abnormal activation disease, and belongs to the technical field of biological medicines. According to the application disclosed by the invention, the small-molecular medicine STK000311 or the pharmaceutically acceptable salt of the small-molecular medicine STK000311 serving as the cGAS-STING signaling pathway inhibitor has an obvious treatment effect on the cGAS-STING pathway abnormal activation diseases for the first time, and verification experiments show that the small-molecular medicine STK000311 can be used for obviously inhibiting the activity of human cGAS protein in a targeted manner and inhibiting cGAS-mediated antiviral immune response; the transcription level of ISGs in PBMCs (peripheral blood mononuclear cells) of an SLE (systemic lupus erythematosus) patient is inhibited, the fact that the small-molecule medicine STK000311 has huge potential of developing cGAS activity related diseases is fully proved, a novel treatment medicine is provided for clinic, and the small-molecule medicine STK000311 has good clinical application value and wide application prospect.

The disclosed method and system pertain to stratifying a patient population for precision medicine in Inflammatory Bowel Disease (IBD) treatment. The method involves accessing a multi-omic dataset comprising genomic, transcriptomic, and proteomic profiles of patient data. Machine learning algorithms are employed to analyze the dataset and identify biomarkers associated with a response to a drug for treating IBD. The patient population is stratified into phenotypic groups based on the identified biomarkers using unsupervised clustering. A patient population predicted to respond to the drug is defined based on the stratification and further analysis of patient metadata. The system includes a data storage unit and a processor configured to perform the method. The method and system can be used to optimize therapeutic interventions in IBD management.

The invention belongs to the technical field of biological medicine, and particularly discloses application of a small molecule compound DRP (Dalicyclic Polymorphism)-104 in preparation of a medicine for treating uveal melanoma. The molecular formula of the DPR-104 is CHNO; an in-vitro experiment proves that the small molecular compound DPR-104 can effectively kill uveal melanoma cells, specifically, proliferation of the uveal melanoma cells is inhibited in an in-vitro concentration-dependent manner, and apoptosis of tumor cells is promoted; animal experiments prove that DPR-104 can effectively kill uveal melanoma in vivo and enhance the effect of uveal melanoma radiotherapy. On the basis, the invention provides a brand-new treatment medicine for uveal melanoma, the treatment effect can be effectively improved, and the life of a patient can be prolonged.

The invention relates to application of bifidobacterium animalis in preparation of a product for preventing, treating or adjunctively treating pneumonia, and belongs to the technical field of microorganisms. The invention aims to solve the technical problem that the existing treatment of acute lung injury (ALI) / acute respiratory distress syndrome (ARDS) is mainly based on supportive means and lacks special-effect treatment drugs. According to the key point of the technical scheme, a new strain, namely the Bifidobacterium animalis ORG01 is provided, the preservation number is GDMCC NO: 67122, and the strain has good technical effects in the aspects of improving the acute lung injury effect, the strain stability, the product application convenience and the like. According to an experimental test, the bifidobacterium animalis ORG01 disclosed by the invention can be used for remarkably recovering the lung organ index of an LPS-induced acute lung injury model mouse, the TNF-alpha content in serum and the mRNA expression level of IL-6 in lung tissues to normal levels.

The invention belongs to the field of biomedical materials, and discloses a preparation method and application of a mesoporous polydopamine nano preparation loaded with ultra-small nano enzyme. The nano preparation takes mesoporous polydopamine nanoparticles as a carrier skeleton and is combined with ultra-small nano enzyme through an in-situ reaction: the mesoporous polydopamine nanoparticles can efficiently carry drugs and accurately deliver the drugs to inflammatory tissues such as psoriasis, gout, colitis and the like by virtue of a modified targeting ligand by virtue of high specific surface area, biocompatibility and modifiability; the ultra-small nano enzyme has catalytic activity of catalase and the like, and can remove active oxygen and relieve oxidative stress. The two components are combined to achieve a synergistic effect, so that the catalytic efficiency of the enzyme is improved by virtue of the characteristics of the carrier, the high activity of the enzyme under different conditions is maintained by virtue of the stability of the carrier, and the platform can synchronously realize targeted delivery, enzymatic treatment and drug controlled release, and has a wide application prospect in the fields of inflammatory disease intervention and wound repair. And an efficient, accurate and low-toxicity universal treatment strategy is provided for chronic inflammatory diseases.

The present invention belongs to the technical field of rapid detection of drug sensitivity for bacteria. Disclosed are an enrichment culture medium, and a preparation method therefor and the use thereof. The enrichment culture medium comprises the following raw materials in parts by mass: 15.0-20.0 parts of tryptone, 3.5-5.5 parts of peptone, 1.5-3.5 parts of glucose, 5.0-6.5 parts of yeast extract, 2.0-2.5 parts of dipotassium phosphate, 2.0-3.5 parts of disodium hydrogen phosphate, 1.0-1.5 parts of monopotassium phosphate, 2.5-7.5 parts of sodium chloride, 12.0-18.0 parts of proteose peptone, 15.0-22.0 parts of beef heart infusion powder, 8.0-12.0 parts of soya peptone, 1.0-5.0 parts of 0.1% nicotinamide adenine dinucleotide (NAD), 30-100 parts of newborn calf serum inactivated at 56°C for 30 min, 2.0-4.0 parts of mannitol, 3.0-5.0 parts of sodium pyruvate, 0.23-0.45 parts of cycloheximide, 0.8-2.0 parts of 0.05% bromothymol blue, 2.5-4.5 parts of 0.1% methylene blue, and 1000 parts of distilled water, with the pH value of 6.8-7.5. The enrichment culture medium is used to screen effective therapeutic drugs for bacterial diseases in poultry, and is convenient to use and has a single enrichment effect superior to that of respective selective enrichment broths of target bacteria. Therefore, the culture medium can realize rapid proliferation of common pathogenic bacteria in poultry.

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

The invention discloses a method for purifying fructus mali pectin and application of the fructus mali pectin in ulcerative colitis, and belongs to the related technical field of separation and purification of natural product bioactive substances and the field of biological medicine. According to the purification method, impurities in the fructus mali pectin can be effectively removed, meanwhile, the structure of the fructus mali pectin cannot be remarkably changed, and the content of galacturonic acid and the esterification degree of the pectin obtained through purification are high. The fructus mali pure pectin can significantly reduce the serum proinflammatory factor level of DSS-induced ulcerative colitis mice, improve the expression of anti-inflammatory factors, and effectively improve the pathological injury of intestinal tissues. According to the invention, a high-efficiency pectin purification system based on macroporous adsorption resin is constructed, and an industrial solution is provided for separation of natural products; meanwhile, the anti-inflammatory mechanism of the fructus mali pure pectin disclosed by the invention lays a scientific foundation for developing medicines and functional foods for treating ulcerative colon.

The invention discloses a periodontal local drug delivery system with antioxidant, anti-inflammatory and antibacterial synergistic effects and a preparation method of the periodontal local drug delivery system, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing an organic phase from DSPC, cholesterol, SA and resveratrol, and preparing a cationic liposome by taking PBS as a water phase; then preparing a water phase from AlgMA and LAP, taking a surfactant solution as an oil phase, and preparing polydopamine hydrogel microspheres through PDA surface modification; and finally, carrying out physical adsorption loading. Through the synergistic effect of the resveratrol, the cationic liposome and the polydopamine, a periodontitis pathological chain is comprehensively intervened, synergistic treatment is achieved, excellent antibacterial performance, anti-inflammatory effect and antioxidant effect are achieved, the retention rate of the medicine is increased, and the problems that traditional treatment medicine cannot achieve antibacterial, inflammation regulation and oxidative stress synergistic treatment at the same time, and the treatment effect is poor are solved. The residence time of the medicine in the periodontal pocket is short, and frequent administration is needed.

This disclosure relates to polyethylene glycol (PEG) -functionalized nanoparticles comprising a functional agent, and preparation methods, properties and applications thereof. The nanoparticle represented by PEG-L-G / P, comprising a type of hydrophilic PEG, a hydrophobic functional agent G, which are covalently linked by L: a linker or a chemical bond, and a type of hydrophobic polymer P. The G and P form the hydrophobic core, while the PEG constitutes the hydrophilic outer layer of the nanoparticle in an aqueous medium. The functional agent comprises one or more functional compounds including a therapeutic drug, an imaging diagnostic agent, a photoelectric responsive diagnostic agent, an immune-stimulating agent, or a combination thereof. The nanoparticles comprising such functional agent can offer various applications in multiple biomedical fields.

The invention discloses a preparation method and application of a sepsis-related encephalopathy model based on HLA II type gene humanized mice. According to the invention, HLA DP401 / DRA-IA beta- / -transgenic humanized mice are utilized, and the HLAII type gene humanized mouse sepsis model is prepared through mouse cecum seroperitoneal infection (CS) and meropenem intervention. The sepsis encephalopathy model can be comprehensively evaluated through indexes such as clinical score MSS, serum and hippocampal tissue inflammatory cytokine detection, hippocampal tissue microglial cell activation, hippocampal neuron spinous process change, transcriptomics, behavioral change and the like, and the sepsis encephalopathy model can be used for screening therapeutic drugs and therapeutic schedules; the HLA II type gene humanized mouse sepsis-related encephalopathy model provided by the invention can be used for infectious encephalopathy pathogenesis research, new drug research and development and safety evaluation.

The invention provides a POCD treatment medicine composition with dendrobine delivered by a nano-carrier and application, and belongs to the technical field of medicine. The composition consists of dendrobine, a nano-carrier material and a stabilizer, wherein a nano-carrier is PLGA (poly (lactic-co-glycolic acid)) nanoparticles or lipidosome. The particle size of the composition is 50-150nm, the polydispersity index is less than 0.3, and the loading capacity of dendrobine is 5-15%. The invention also provides two preparation methods of the composition. The PLGA nanoparticles are prepared by adopting an emulsification-solvent evaporation method; the liposome is prepared by adopting a film hydration-ultrasonic extrusion method, and each process parameter is specifically limited. The pharmaceutical composition can significantly improve the brain targeting and bioavailability of dendrobine, and can be used for preparing drugs for preventing or treating postoperative cognitive impairment (POCD), and the administration route can be intravenous injection or nasal administration.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

The invention relates to the technical field of medical treatment, and particularly discloses dihydroartemisinin-loaded nano-hydrogel, which is prepared from the following components: 5 to 20 percent of gelatin methacryloyl, 5 to 15 percent of nano-hydroxyapatite and 0.5 to 2 percent of dihydroartemisinin, according to the invention, through the constructed Ge MA-nHA-DHA functionalized hydrogel system, the local concentration and bioavailability of dihydroartemisinin are remarkably improved, and the repair and regeneration of bone tissues are promoted. Research results show that the system can effectively inhibit inflammatory response, promote proliferation and differentiation of osteoblasts, improve the structure and function of bone tissues, slow down further collapse of femoral heads and finally improve the living quality of patients. In addition, the biological material shows good biocompatibility and appropriate drug release characteristics when applied in vivo, and a novel effective means is provided for treatment of steroid-induced femoral head necrosis.